Concepts (196)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 13 | 2022 | 206 | 2.430 |
Why?
|
| Laparoscopy | 12 | 2010 | 237 | 1.960 |
Why?
|
| Prostatic Neoplasms | 14 | 2021 | 778 | 1.930 |
Why?
|
| Nephrectomy | 9 | 2019 | 103 | 1.450 |
Why?
|
| Carcinoma, Renal Cell | 7 | 2022 | 110 | 1.280 |
Why?
|
| Fluoroquinolones | 2 | 2016 | 49 | 1.040 |
Why?
|
| Prostate-Specific Antigen | 2 | 2016 | 138 | 1.010 |
Why?
|
| Penile Neoplasms | 2 | 2011 | 12 | 0.780 |
Why?
|
| Prostatectomy | 7 | 2021 | 87 | 0.730 |
Why?
|
| Allostasis | 1 | 2020 | 6 | 0.720 |
Why?
|
| Societies, Medical | 9 | 2022 | 403 | 0.690 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 43 | 0.680 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 1026 | 0.660 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2018 | 6 | 0.640 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 33 | 0.610 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2022 | 446 | 0.540 |
Why?
|
| Kidney | 5 | 2009 | 945 | 0.510 |
Why?
|
| Carcinoma, Transitional Cell | 5 | 2018 | 41 | 0.490 |
Why?
|
| Humans | 54 | 2022 | 68618 | 0.460 |
Why?
|
| Radiotherapy | 1 | 2013 | 86 | 0.430 |
Why?
|
| Ureteral Neoplasms | 4 | 2018 | 8 | 0.430 |
Why?
|
| Veterans | 1 | 2020 | 904 | 0.420 |
Why?
|
| Male | 33 | 2022 | 37321 | 0.410 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 581 | 0.400 |
Why?
|
| Penis | 1 | 2011 | 25 | 0.390 |
Why?
|
| Cryosurgery | 2 | 2010 | 53 | 0.390 |
Why?
|
| Pyelonephritis | 2 | 2022 | 17 | 0.380 |
Why?
|
| Delayed Diagnosis | 1 | 2011 | 39 | 0.370 |
Why?
|
| Robotics | 1 | 2011 | 56 | 0.370 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1070 | 0.370 |
Why?
|
| Prostate | 3 | 2017 | 116 | 0.370 |
Why?
|
| Evidence-Based Medicine | 7 | 2022 | 438 | 0.370 |
Why?
|
| Robotic Surgical Procedures | 2 | 2021 | 49 | 0.360 |
Why?
|
| Ureteroscopy | 2 | 2018 | 5 | 0.340 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2005 | 138 | 0.330 |
Why?
|
| Infusion Pumps | 1 | 2009 | 39 | 0.330 |
Why?
|
| Diagnostic Imaging | 3 | 2021 | 201 | 0.330 |
Why?
|
| Watchful Waiting | 3 | 2022 | 25 | 0.320 |
Why?
|
| Narcotics | 1 | 2009 | 65 | 0.320 |
Why?
|
| Anesthetics, Local | 1 | 2009 | 83 | 0.310 |
Why?
|
| Neoplasm Seeding | 1 | 2007 | 7 | 0.310 |
Why?
|
| Aged | 19 | 2020 | 14862 | 0.300 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 955 | 0.300 |
Why?
|
| Length of Stay | 2 | 2009 | 780 | 0.290 |
Why?
|
| Kidney Pelvis | 3 | 2004 | 12 | 0.290 |
Why?
|
| Cystectomy | 2 | 2004 | 13 | 0.280 |
Why?
|
| Operating Rooms | 3 | 2022 | 108 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 629 | 0.270 |
Why?
|
| Middle Aged | 15 | 2020 | 21147 | 0.270 |
Why?
|
| United States | 13 | 2022 | 7367 | 0.260 |
Why?
|
| Urothelium | 3 | 2018 | 22 | 0.260 |
Why?
|
| Cholecalciferol | 3 | 2016 | 143 | 0.230 |
Why?
|
| Radiology | 2 | 2021 | 97 | 0.220 |
Why?
|
| Ultrasonography | 4 | 2022 | 453 | 0.220 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2021 | 26 | 0.210 |
Why?
|
| Polymyositis | 1 | 2002 | 5 | 0.210 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2002 | 9 | 0.210 |
Why?
|
| Hematuria | 3 | 2020 | 24 | 0.210 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 71 | 0.200 |
Why?
|
| Patient Portals | 1 | 2021 | 12 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2022 | 2223 | 0.190 |
Why?
|
| Treatment Failure | 2 | 2013 | 216 | 0.190 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 800 | 0.190 |
Why?
|
| Muscles | 1 | 2001 | 158 | 0.180 |
Why?
|
| Renal Veins | 1 | 2000 | 18 | 0.180 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2000 | 28 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2021 | 121 | 0.170 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 4848 | 0.170 |
Why?
|
| Adenocarcinoma | 2 | 2017 | 475 | 0.170 |
Why?
|
| Risk Factors | 7 | 2020 | 5731 | 0.170 |
Why?
|
| Social Determinants of Health | 1 | 2020 | 96 | 0.170 |
Why?
|
| Biopsy | 2 | 2018 | 540 | 0.170 |
Why?
|
| Minority Groups | 1 | 2020 | 197 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2020 | 170 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 114 | 0.150 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 445 | 0.150 |
Why?
|
| Retrospective Studies | 6 | 2022 | 7277 | 0.150 |
Why?
|
| Hypertension, Renovascular | 1 | 2017 | 47 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 334 | 0.150 |
Why?
|
| Prospective Studies | 4 | 2022 | 3705 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 170 | 0.150 |
Why?
|
| Administration, Oral | 1 | 2018 | 411 | 0.150 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 951 | 0.140 |
Why?
|
| Neoplasm Invasiveness | 2 | 2011 | 369 | 0.140 |
Why?
|
| Carcinoma | 2 | 2012 | 215 | 0.140 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 848 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2018 | 215 | 0.140 |
Why?
|
| Radiography | 2 | 2012 | 572 | 0.140 |
Why?
|
| Systems Analysis | 1 | 2016 | 33 | 0.130 |
Why?
|
| Contrast Media | 1 | 2019 | 595 | 0.130 |
Why?
|
| Prostatitis | 1 | 2016 | 10 | 0.130 |
Why?
|
| Dietary Supplements | 3 | 2016 | 332 | 0.130 |
Why?
|
| Transcriptome | 1 | 2016 | 164 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 772 | 0.120 |
Why?
|
| Biomarkers | 1 | 2020 | 1593 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 320 | 0.120 |
Why?
|
| Exercise | 1 | 2020 | 658 | 0.120 |
Why?
|
| Female | 12 | 2022 | 38074 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 508 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 2279 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 3 | 2020 | 307 | 0.110 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2013 | 14 | 0.110 |
Why?
|
| Prognosis | 3 | 2017 | 2093 | 0.110 |
Why?
|
| Quality of Life | 2 | 2020 | 1515 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 627 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2013 | 82 | 0.100 |
Why?
|
| Adult | 7 | 2020 | 21403 | 0.100 |
Why?
|
| Urologic Surgical Procedures, Male | 1 | 2011 | 20 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 91 | 0.100 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 274 | 0.090 |
Why?
|
| Ureteral Obstruction | 2 | 2000 | 25 | 0.090 |
Why?
|
| Urinary Diversion | 2 | 2000 | 16 | 0.090 |
Why?
|
| Nephrons | 1 | 2009 | 17 | 0.090 |
Why?
|
| Insurance, Health | 1 | 2011 | 201 | 0.080 |
Why?
|
| Endoscopy | 2 | 2004 | 464 | 0.080 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 85 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2020 | 2007 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2020 | 2358 | 0.080 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 111 | 0.080 |
Why?
|
| Comorbidity | 2 | 2020 | 1426 | 0.070 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2006 | 49 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 144 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1851 | 0.060 |
Why?
|
| Specimen Handling | 1 | 2005 | 47 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 3259 | 0.060 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 805 | 0.060 |
Why?
|
| Living Donors | 1 | 2006 | 160 | 0.060 |
Why?
|
| Forecasting | 1 | 2005 | 277 | 0.060 |
Why?
|
| Urologic Surgical Procedures | 2 | 2000 | 47 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2011 | 1615 | 0.060 |
Why?
|
| Kidney Calices | 1 | 2003 | 2 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2013 | 7029 | 0.050 |
Why?
|
| Kidney Calculi | 1 | 2003 | 19 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2324 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2004 | 299 | 0.050 |
Why?
|
| Polyps | 1 | 2000 | 12 | 0.050 |
Why?
|
| Ureter | 1 | 2000 | 16 | 0.050 |
Why?
|
| Diathermy | 1 | 2000 | 5 | 0.050 |
Why?
|
| Infertility, Male | 1 | 2000 | 35 | 0.050 |
Why?
|
| Morbidity | 1 | 2001 | 130 | 0.050 |
Why?
|
| Efficiency | 1 | 2021 | 49 | 0.050 |
Why?
|
| Ultrasonic Therapy | 1 | 2000 | 19 | 0.050 |
Why?
|
| Photons | 1 | 2000 | 32 | 0.050 |
Why?
|
| Microwaves | 1 | 2000 | 31 | 0.050 |
Why?
|
| Workflow | 1 | 2021 | 100 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 1753 | 0.040 |
Why?
|
| Laser Therapy | 1 | 2000 | 54 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 129 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 38 | 0.040 |
Why?
|
| Quality Control | 1 | 2019 | 81 | 0.040 |
Why?
|
| Patient Safety | 1 | 2021 | 202 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2019 | 191 | 0.040 |
Why?
|
| Nephroureterectomy | 1 | 2018 | 1 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2019 | 219 | 0.040 |
Why?
|
| Kidney Transplantation | 1 | 2006 | 839 | 0.040 |
Why?
|
| Surgical Instruments | 1 | 2018 | 44 | 0.040 |
Why?
|
| Cancer Survivors | 1 | 2020 | 146 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2000 | 307 | 0.040 |
Why?
|
| Health Status | 1 | 2020 | 429 | 0.040 |
Why?
|
| Alloys | 1 | 2018 | 66 | 0.040 |
Why?
|
| Hospitals, Veterans | 1 | 2017 | 147 | 0.040 |
Why?
|
| Acute Disease | 1 | 2018 | 658 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1174 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2077 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 109 | 0.040 |
Why?
|
| Stents | 1 | 2000 | 657 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1619 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1140 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1465 | 0.030 |
Why?
|
| Patient Selection | 1 | 2017 | 592 | 0.030 |
Why?
|
| Erectile Dysfunction | 1 | 2013 | 22 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 67 | 0.030 |
Why?
|
| International System of Units | 1 | 2012 | 6 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 349 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.030 |
Why?
|
| Risk | 1 | 2012 | 563 | 0.020 |
Why?
|
| Ileum | 2 | 2000 | 28 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 447 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2012 | 285 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 1056 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 292 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 378 | 0.020 |
Why?
|
| Vitamin D | 1 | 2012 | 516 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1745 | 0.020 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2004 | 5 | 0.020 |
Why?
|
| Digestive System Neoplasms | 1 | 2004 | 13 | 0.020 |
Why?
|
| Choledocholithiasis | 1 | 2004 | 14 | 0.020 |
Why?
|
| Case Management | 1 | 2004 | 46 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2004 | 164 | 0.010 |
Why?
|
| Bone Neoplasms | 1 | 2004 | 100 | 0.010 |
Why?
|
| Time Factors | 1 | 2012 | 4655 | 0.010 |
Why?
|
| Palliative Care | 1 | 2004 | 271 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 468 | 0.010 |
Why?
|
| Ohio | 1 | 2000 | 64 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2004 | 1173 | 0.010 |
Why?
|